Target intelligence / Profile preview

Hepatitis B virus RNA (HBV RNA)

Target
HBV RNA
Molecular classification
Other, Viral RNA
01

Overview

Hepatitis B virus (HBV) RNA transcripts represent a critical therapeutic target for achieving a functional cure in patients with chronic hepatitis B infection. The HBV genome is highly compact, utilizing four overlapping open reading frames transcribed from covalently closed circular DNA (cccDNA) or integrated viral DNA into multiple overlapping transcripts that share a common 3' polyadenylation signal. Because of this unique overlapping structure, therapeutic agents such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) can target conserved 3' regions to simultaneously degrade all major viral transcripts, including pregenomic RNA (pgRNA) and messenger RNAs encoding HBsAg, HBeAg, and viral polymerase. This degradation halts the production of viral proteins that act as immune tolerogens, thereby suppressing viral replication and potentially restoring the host's innate and adaptive immune responses. Clinical candidates targeting these transcripts, such as bepirovirsen, imdusiran, and elebsiran, have demonstrated significant and sustained reductions in circulating HBsAg levels, offering a promising finite treatment strategy to achieve functional cure.

Other names
overlapping HBV transcriptsHepatitis B virus transcriptsHBV transcriptsHepatitis B virus pregenomic RNAHBV pgRNAHepatitis B virus messenger RNAHBV mRNAHBV RNA / overlapping HBV transcripts
02

Mechanism of action

Degradation of viral transcripts via RNA interference (RNAi) using small interfering RNAs (siRNAs) or RNase H-mediated cleavage using antisense oligonucleotides (ASOs), thereby preventing the translation of viral proteins and inhibiting viral replication.

03

Biological functions

OtherViral replicationTranslation
04

Disease associations

InfectionCancerInflammation
05

Safety considerations

Alanine aminotransferase (ALT) flares / transient transaminase elevationsThrombocytopeniaInjection-site reactionsOff-target RNAi-mediated effectsRenal clearance challenges or mild reduction of estimated glomerular filtration rate (eGFR)Risk of viral rebound or relapse after treatment discontinuation
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

Hepatitis B surface antigen (HBsAg) levelsSerum HBV RNA levelsHepatitis B virus DNA (HBV DNA) levelsHepatitis B e antigen (HBeAg) levelsHepatitis B core-related antigen (HBcrAg) levelsAlanine aminotransferase (ALT) levels

Beyond the preview

Go deeper on Hepatitis B virus RNA (HBV RNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatitis B virus RNA (HBV RNA).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call